NCT03268226已完成3 期
Open Label, Prospective, Exploratory Study to Investigate the Effect of Inhaled CHF5993 pMDI on Central and Peripheral Airway Dimensions in COPD Patients by Functional Respiratory Imaging
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 5
- 主要终点
- Specific image-based airway volumes (siVaw)
研究概览
简要总结
The purpose of this study is to evaluate the effect of inhaled extrafine CHF5993 pMDI on airway volumes, and resistance, by Functional Respiratory Imaging (FRI), in COPD patients
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject's written informed consent obtained prior to any study-related procedure.
- •Male or Female COPD patients aged ≥ 40 years.
- •Smoking history: of at least 10 pack-years (pack-year= number of cigarettes per day x number of years/20).
- •Smoking status: current or ex-smokers. Previous smokers are defined as those who have stopped smoking for at least 24 weeks prior to screening visit. (Pipe and/or cigar and/or e-cigarettes smoking cannot be used to calculate pack-year history). If the subjects undergo smoking cessation therapy, it must be completed 3 months prior to study entry.
- •Patients with documented COPD at least 12 months according to GOLD
- •Post-bronchodilator (BD) decreased Tiffeneau index: FEV1/FVC < 0.
- •Patients who present post- BD FEV1 less than 50 % of predicted.
- •Patients who present (Functional residual capacity) FRC ≥120% predicted.
- •Patients who present CAT assessment ≥
- •Patients on stable respiratory medications for at least 3 months prior to screening with non extrafine extemporary triple combination. The possible combination therapies prior to screening are:
- •fluticasone plus salmeterol plus tiotropium
- •fluticasone plus salmeterol plus glycopyrronium
- •fluticasone plus salmeterol plus umeclidinium
- •fluticasone plus vilanterol plus tiotropium
- •fluticasone plus vilanterol plus glycopyrronium
- •fluticasone plus vilanterol plus umeclidinium;
- •Body Mass Index (BMI) between 18.0 and 32.0 kg/m2 (extremes included) at the screening visit..
- •Ability to understand the study procedures and the risks involved and ability to be trained with pMDI training inhalers to use the devices correctly.
- •WOCBP fulfilling one of the following criteria:
- •WOCBP with fertile male partners: they and/or their partner must be willing to use a highly effective birth control method from the signature of the informed consent and until the follow-up visit or
- •WOCBP with non-fertile male partners (contraception is not required in this case).
- •For the definition of WOCBP and of fertile men and the list of highly effective birth control methods, refer the CTFG guidance for more detailed information
- •Female patients of non-childbearing potential defined as physiologically incapable of becoming pregnant (i.e. post-menopausal or permanently sterile; e.g. amenorrehic for ≥12 consecutive months without alternative medical cause). Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy (40). If indicated, as per investigator's request, post-menopausal status may be confirmed by follicle-stimulating hormone levels (according to local laboratory ranges).
排除标准
- •Pregnant or lactating women.
- •Patients with history or current diagnosis of asthma.
- •Medical history or current diagnosis of allergic rhinitis or atopy (atopy which may have risen contra-indications or impacted the efficacy of the study treatment according to Investigator's judgment).
- •Patients requiring use of the following medications:
- •Systemic steroids for COPD exacerbation in the 4 weeks prior to screening;
- •Patients with a moderate or severe COPD exacerbation [i.e. resulting in the use of systemic corticosteroids (oral/IV/IM) and/or or antibiotics or need for hospitalisation within 6 weeks prior to screening];
- •A course of antibiotics for COPD exacerbation longer than 7 days in the 4 weeks prior to screening;
- •c-Phosphodiesterase-4 (PDE-4) inhibitors in the 4 weeks prior to screening;
- •Use of antibiotics for a lower respiratory tract infection (e.g. pneumonia) in the 4 weeks prior to screening;
- •Patients treated with non-cardio-selective β-blockers in the week prior to screening.
- •Patients treated with long-acting anti-histamines unless taken at stable regimen at least 2 months prior to screening and to be maintained constant during the study.
- •Patients requiring long term (at least 12 hours daily) oxygen therapy for chronic hypoxemia.
- •Known respiratory disorders other than COPD which may impact the efficacy of the study treatment according the Investigator's judgment. (This could include but is not limited to α-1 antitrypsin deficiency, active tuberculosis, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension and interstitial lung disease).
- •Lung cancer or history of lung cancer: patients with a diagnosis of lung cancer or a history of lung cancer.
- •Lung resection: subjects with a history of lung volume resection.
- •Subjects who have a cardiovascular condition such as, but not limited to unstable ischemic heart disease, NYHA Class III/IV left ventricular failure, acute ischemic heart disease in the last year prior to study screening, which may impact the safety of the subject or the evaluation of the result of the study according to the Investigator's judgment; history of atrial fibrillation, history of sustained and non sustained cardiac arrhythmias diagnosed within 24 weeks prior to study entry not controlled with therapy.
- •ECG criteria: any clinically significant abnormal 12-lead ECG that in the Investigator's opinion would affect the efficacy or safety evaluation or place the patients at risk. Male patients with a QTcF >450ms and female patients with a QTcF >470ms at screening and/or baseline visits are not eligible.
- •Medical history or current diagnosis of narrow-angle glaucoma, clinically relevant prostatic hypertrophy or bladder neck obstruction that in the opinion of the Investigator would have prevented use of anticholinergic agents.
- •History of hypersensitivity to M3 antagonists, β2-agonist, corticosteroids or any of the excipients contained in any of the formulations used in the study which may raise contra-indications or impacted the efficacy of the study treatment according to the Investigator's judgment.
- •Clinically significant laboratory abnormalities indicating a significant or unstable concomitant disease which may have impacted the efficacy or the safety of the study treatment according to Investigator's judgment.
- •Patients with serum potassium levels < 3.5 mEq/L (or 3.5 mmol/L).
- •Unstable concurrent disease: e.g. uncontrolled hyperthyroidism, uncontrolled diabetes mellitus or other endocrine disease; uncontrolled gastrointestinal disease (e.g. active peptic ulcer); uncontrolled neurological disease; uncontrolled hematological disease; uncontrolled autoimmune disorders, or other which may impact the feasibility of the results of the study according to Investigator's judgment.
- •History of alcohol abuse and/or substance/drug abuse within 12 months prior to screening.
- •Drugs with hepatoxic potential: Patients receiving treatment with any drug known to have a well defined potential for hepatotoxicity (e.g. isoniazide, nimesulide, ketoconazole) within the previous 3 months before the screening visit.
- •Changes in dose, schedule, formulation or product of oral xanthine derivatives (e.g. Theophylline) in the month prior screening visit.
- •Participation in an investigational trial: patients who have received any investigational drug within the 30 days (60 days for biologics) before the screening visit or a more appropriate time as determined by the investigator (e.g. approximately 5 half-lives of the investigational drug whatever is longer).
- •Treatment with strong CYP3A inhibitors (e.g. erythromycin, itraconazole) within 4 weeks prior to study entry.
- •Serology at the screening positive for HIV1 or HIV2 and positive results for Hepatitis which indicates acute or chronic Hepatitis B (i.e. positive HB surface antigen HBsAg, positive and/or positive HB core antibody anti-HBc) or Hepatitis C (positive HCV antibody).
研究组 & 干预措施
CHF5993
Experimental
Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium Bromide administered via pMDI
干预措施: Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium (Drug)
结局指标
主要结局
Specific image-based airway volumes (siVaw)
时间窗: Change from baseline at 24 Weeks.
CT-based airway volumes normalized by the lung volume
Specific image-based airway resistance (siRaw)
时间窗: Change from baseline at 24 Weeks.
CFD-based airway resistance normalized by the lung volume
次要结局
- Ventilation/perfusion matching(On Week 0, Week 12, and on Week 24)
- Quality of life(On Week 0, Week 12, and on Week 24)
- Internal Airflow Distribution(On Week 0, Week 12, and on Week 24)
- Air Trapping(On Week 0, Week 12, and on Week 24)
- Blood vessel density(On Week 0, Week 12, and on Week 24)
- Emphysema(On Week 0, Week 12, and on Week 24)
- Airway Wall Volume(On Week 0, Week 12, and on Week 24)
- Aerosol Deposition(On Week 0, Week 12, and on Week 24)
- Functional Dyspnea(On Week 0, Week 12, and on Week 24)
- CAT score(On Week 0, Week 12, and on Week 24)
- Static lung volumes(On Week 0, Week 12, and on Week 24)
- Dyspnea(On Week 0, Week 12, and on Week 24)
- Dynamic lung volumes(On Week 0, Week 12, and on Week 24)
- airway resistances(On Week 0, Week 12, and on Week 24)
研究者
研究点 (5)
Loading locations...
相似试验
已完成
2 期
Dose Response AMP Challenge Study With Beclometasone Dipropionate (BDP)/Formoterol Pressurised Metered Dose Inhaler (pMDI)Mild Persistent AsthmaNCT01343745Chiesi Farmaceutici S.p.A.18
已完成
3 期
Efficacy Study of the Product "CHF 1535" Versus Beclomethasone (BDP) and Free Combo in Asthmatic ChildrenAsthmaNCT01475032Chiesi Farmaceutici S.p.A.638
撤回
1 期
Study of Airway Inflammatory Responses to Experimental Rhinovirus InfectionHealthy VolunteersRhinovirusNCT03508479University of North Carolina, Chapel Hill23
已完成
2 期
PT005 MDI Dose Ranging Versus Foradil Aerolizer StudyChronic Obstructive Pulmonary DiseaseNCT01349868Pearl Therapeutics, Inc.50
已完成
不适用
Evaluation of Exhaled Breath Condensate in the Diagnosis of Invasive Pulmonary AspergillosisInvasive Pulmonary AspergillosisNCT01247142Universitaire Ziekenhuizen KU Leuven24